kabutan

Ajinomoto Co., Inc.(2802) Summary

2802
TSE Prime
Ajinomoto Co., Inc.
4,767
JPY
-19
(-0.40%)
Apr 28, 3:30 pm JST
29.94
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
4,678
Apr 28, 11:52 pm JST
Summary Chart Historical News Financial Result
PER
35.1
PBR
6.14
Yield
1.01%
Margin Trading Ratio
0.93
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
4,794 JPY 30.08 USD
Previous Close Apr 27
4,786 JPY 30.02 USD
High Apr 28, 9:00 am
4,813 JPY 30.20 USD
Low Apr 28, 9:25 am
4,750 JPY 29.80 USD
Volume
2,409,700
Trading Value
0.01T JPY 0.07B USD
VWAP
4770.4 JPY 29.96 USD
Minimum Trading Value
476,700 JPY 2,994 USD
Market Cap
4.66T JPY 0.03T USD
Number of Trades
4,385
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
5,723
1-Year High Feb 6, 2026
27,071
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 147,400 882,000 5.98
Apr 17, 2026 135,200 891,000 6.59
Apr 10, 2026 151,900 797,100 5.25
Apr 3, 2026 144,800 890,000 6.15
Mar 27, 2026 280,200 940,300 3.36
Company Profile
Ajinomoto Co., Inc. is a leading comprehensive food company, ranking first in seasonings. The company has diversified into pharmaceuticals, animal feed, and other sectors, and is actively pursuing M&A opportunities.
Sector
Foods
Ajinomoto Co., Inc. is a comprehensive food manufacturer with a primary focus on seasonings, nutritional and processed foods, solution and ingredients, and frozen foods. The company also operates in non-food sectors, including pharmaceutical and food-grade amino acids, biopharmaceutical services (CDMO), and functional materials (such as electronic materials). With numerous subsidiaries both domestically and internationally, Ajinomoto conducts business on a global scale. The company has particularly strong business foundations in Southeast Asia and South America. In the seasoning business, Ajinomoto has local subsidiaries in Thailand, Indonesia, Vietnam, the Philippines, and Malaysia, among others. The frozen food business has also expanded into North America. Additionally, the company is focusing on strengthening its biopharmaceutical services business.